Evidence map›Paper›PMID 38089570›Full record

ArticleiScience2023

Wild-type C-Raf gene dosage and dimerization drive prostate cancer metastasis.

Lisa Ta, Brandon L Tsai, Weixian Deng, Jihui Sha, Grigor Varuzhanyan, Wendy Tran, James A Wohlschlegel, Janai R Carr-Ascher, Owen N Witte

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Lisa TaDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Brandon L TsaiDepartment of Human Genetics, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Weixian DengDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Jihui ShaDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Grigor VaruzhanyanDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Wendy TranDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles; Los Angeles, CA 90095, USA.
James A WohlschlegelDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles; Los Angeles, CA 90095, USA.
Janai R Carr-AscherDepartment of Internal Medicine, Division of Hematology/Oncology, University of California, Davis, Sacramento, CA 95817, USA.
Owen N WitteDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles; Los Angeles, CA 90095, USA.
University of California, Los Angeles · USUniversity of California Davis Medical Center · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development ProgramK12CA138464 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BIRKELAND, ANDREW CHARLES, LARA, PRIMO N. · 2011 to 2025
$11.4M
Astrocyte and neuron brain-region and compartment-specific proteome dynamics in aging and Alzheimer’s diseaseR01AG075955 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KHAKH, BALJIT, VOSSEL, KEITH ALAN · 2021 to 2025
$5.2M
Proteolytic Control of Iron Metabolism by the Ubiquitin Ligase FBXL5R01GM089778 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WOHLSCHLEGEL, JAMES AKIRA · 2010 to 2023
$4.0M
NCI NIH HHS K12 CA138464NCI NIH HHS P30 CA093373NIA NIH HHS R01 AG075955NIGMS NIH HHS R01 GM089778
6 · The paper itself

Abstract

Mutated Ras and Raf kinases are well-known to promote cancer metastasis via flux through the Ras/Raf/MEK/ERK (mitogen-activated protein kinase [MAPK]) pathway. A role for non-mutated Raf in metastasis is also emerging, but the key mechanisms remain unclear. Elevated expression of any of the three wild-type Raf family members (C, A, or B) can drive metastasis. We utilized an

Indexed as

BiochemistryCancerMolecular biologyProteomicsTranscriptomics

Identifiers

PMID38089570
PMCPMC10711388
OpenAlexW4388751880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.